Catalysts for Daiichi Sankyo Co Ltd
19 tracked
Apr 30, 2026
phase 1 completion
Daiichi Sankyo Co Ltd — raludotatug deruxtecan (Phase I Trial Completion)
raludotatug deruxtecan
→
Apr 24, 2026
drug expiry
Daiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))
laninamivir
→
Apr 24, 2026
patent expiry
Daiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))
laninamivir
→
Apr 13, 2026
approval
VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approval
quizartinib dihydrochloride
→
Dec 15, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 15, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jun 25, 2024
approval
VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approval
quizartinib dihydrochloride
→
Apr 5, 2024
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Feb 15, 2024
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jul 20, 2023
approval
VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — FDA approval
quizartinib dihydrochloride
→
Nov 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 11, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 5, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 15, 2021
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 20, 2019
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→